Intensive chemotherapy of small cell bronchogenic carcinoma

M. H. Cohen, P. J. Creaven, B. E. Fossieck, L. E. Broder, O. S. Selawry, A. V. Johnston, C. L. Williams, J. D. Minna

Research output: Contribution to journalArticle

205 Citations (Scopus)

Abstract

Thirty two patients (27, extensive disease; 5, regional disease) with histologically documented small cell carcinoma entered a randomized study to determine the efficacy of intensive induction chemotherapy. The necessity of a protected environment (laminar air flow room) during this treatment was also evaluated. Patients received high dose or standard dose cyclophosphamide, methotrexate, and CCNU (CMC) during the first 6 wk of treatment. Subsequent maintenance therapy consisted of standard dose CMC until disease progression. In 23 patients treated with high dose chemotherapy there were responses in 96% (30% complete). Standard dose chemotherapy gave responses in 45%, none of which were complete. Median survival correlated with completeness of response and was 16+ months for the 7 complete responders. Patients receiving high dose CMC spent an average of 10 days with neutrophil counts <1000/mm 3. There was only one documented, non fatal infection. High dose chemotherapy gives better responses and longer survival than previously utilized standard doses of the same drugs. Patients could safely be treated in the hospital ward.

Original languageEnglish (US)
Pages (from-to)349-354
Number of pages6
JournalCancer Treatment Reports
Volume61
Issue number3
StatePublished - 1977

Fingerprint

Small Cell Carcinoma
Bronchogenic Carcinoma
Lomustine
Drug Therapy
Methotrexate
Cyclophosphamide
Induction Chemotherapy
Survival
Disease Progression
Neutrophils
Therapeutics
Air
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cohen, M. H., Creaven, P. J., Fossieck, B. E., Broder, L. E., Selawry, O. S., Johnston, A. V., ... Minna, J. D. (1977). Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treatment Reports, 61(3), 349-354.

Intensive chemotherapy of small cell bronchogenic carcinoma. / Cohen, M. H.; Creaven, P. J.; Fossieck, B. E.; Broder, L. E.; Selawry, O. S.; Johnston, A. V.; Williams, C. L.; Minna, J. D.

In: Cancer Treatment Reports, Vol. 61, No. 3, 1977, p. 349-354.

Research output: Contribution to journalArticle

Cohen, MH, Creaven, PJ, Fossieck, BE, Broder, LE, Selawry, OS, Johnston, AV, Williams, CL & Minna, JD 1977, 'Intensive chemotherapy of small cell bronchogenic carcinoma', Cancer Treatment Reports, vol. 61, no. 3, pp. 349-354.
Cohen MH, Creaven PJ, Fossieck BE, Broder LE, Selawry OS, Johnston AV et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treatment Reports. 1977;61(3):349-354.
Cohen, M. H. ; Creaven, P. J. ; Fossieck, B. E. ; Broder, L. E. ; Selawry, O. S. ; Johnston, A. V. ; Williams, C. L. ; Minna, J. D. / Intensive chemotherapy of small cell bronchogenic carcinoma. In: Cancer Treatment Reports. 1977 ; Vol. 61, No. 3. pp. 349-354.
@article{771e2faadca34f3a90103e52dc37045c,
title = "Intensive chemotherapy of small cell bronchogenic carcinoma",
abstract = "Thirty two patients (27, extensive disease; 5, regional disease) with histologically documented small cell carcinoma entered a randomized study to determine the efficacy of intensive induction chemotherapy. The necessity of a protected environment (laminar air flow room) during this treatment was also evaluated. Patients received high dose or standard dose cyclophosphamide, methotrexate, and CCNU (CMC) during the first 6 wk of treatment. Subsequent maintenance therapy consisted of standard dose CMC until disease progression. In 23 patients treated with high dose chemotherapy there were responses in 96{\%} (30{\%} complete). Standard dose chemotherapy gave responses in 45{\%}, none of which were complete. Median survival correlated with completeness of response and was 16+ months for the 7 complete responders. Patients receiving high dose CMC spent an average of 10 days with neutrophil counts <1000/mm 3. There was only one documented, non fatal infection. High dose chemotherapy gives better responses and longer survival than previously utilized standard doses of the same drugs. Patients could safely be treated in the hospital ward.",
author = "Cohen, {M. H.} and Creaven, {P. J.} and Fossieck, {B. E.} and Broder, {L. E.} and Selawry, {O. S.} and Johnston, {A. V.} and Williams, {C. L.} and Minna, {J. D.}",
year = "1977",
language = "English (US)",
volume = "61",
pages = "349--354",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Intensive chemotherapy of small cell bronchogenic carcinoma

AU - Cohen, M. H.

AU - Creaven, P. J.

AU - Fossieck, B. E.

AU - Broder, L. E.

AU - Selawry, O. S.

AU - Johnston, A. V.

AU - Williams, C. L.

AU - Minna, J. D.

PY - 1977

Y1 - 1977

N2 - Thirty two patients (27, extensive disease; 5, regional disease) with histologically documented small cell carcinoma entered a randomized study to determine the efficacy of intensive induction chemotherapy. The necessity of a protected environment (laminar air flow room) during this treatment was also evaluated. Patients received high dose or standard dose cyclophosphamide, methotrexate, and CCNU (CMC) during the first 6 wk of treatment. Subsequent maintenance therapy consisted of standard dose CMC until disease progression. In 23 patients treated with high dose chemotherapy there were responses in 96% (30% complete). Standard dose chemotherapy gave responses in 45%, none of which were complete. Median survival correlated with completeness of response and was 16+ months for the 7 complete responders. Patients receiving high dose CMC spent an average of 10 days with neutrophil counts <1000/mm 3. There was only one documented, non fatal infection. High dose chemotherapy gives better responses and longer survival than previously utilized standard doses of the same drugs. Patients could safely be treated in the hospital ward.

AB - Thirty two patients (27, extensive disease; 5, regional disease) with histologically documented small cell carcinoma entered a randomized study to determine the efficacy of intensive induction chemotherapy. The necessity of a protected environment (laminar air flow room) during this treatment was also evaluated. Patients received high dose or standard dose cyclophosphamide, methotrexate, and CCNU (CMC) during the first 6 wk of treatment. Subsequent maintenance therapy consisted of standard dose CMC until disease progression. In 23 patients treated with high dose chemotherapy there were responses in 96% (30% complete). Standard dose chemotherapy gave responses in 45%, none of which were complete. Median survival correlated with completeness of response and was 16+ months for the 7 complete responders. Patients receiving high dose CMC spent an average of 10 days with neutrophil counts <1000/mm 3. There was only one documented, non fatal infection. High dose chemotherapy gives better responses and longer survival than previously utilized standard doses of the same drugs. Patients could safely be treated in the hospital ward.

UR - http://www.scopus.com/inward/record.url?scp=0017701402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017701402&partnerID=8YFLogxK

M3 - Article

C2 - 194691

AN - SCOPUS:0017701402

VL - 61

SP - 349

EP - 354

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -